Clinical Trial Update: Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating bortezomib, lenalidomide, and IV busulfan in patients under 65 with multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Busulfan (IV) (busulfan)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: PETHEMA Foundation | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED